Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Presented New Patient-Reported Outcomes Data for Olorinab at the European Society of Neurogastroenterology & Motility NeuroGASTRO 2019 Meeting
SAN DIEGO , Sept. 9, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting, highly-selective, full agonist of the cannabinoid receptor 2 (CB 2 ) in development for the treatment of
View HTML
Toggle Summary Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO , Aug. 28, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences: Wells Fargo Global Healthcare Conference – Presenting on Wednesday, September 4 , at 8:30 AM EDT in
View HTML
Toggle Summary Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Initiation of Etrasimod ELEVATE UC 52 and Olorinab CAPTIVATE Trials
- Etrasimod initiation of the Phase 3 ELEVATE UC 52 global trial in ulcerative colitis (UC) - Olorinab initiation of the Phase 2 CAPTIVATE clinical trial in abdominal pain associated with irritable bowel syndrome (IBS) - Multiple first- or best-in-class drug candidates, skilled leadership team and
View HTML
Toggle Summary Arena Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on August 7
SAN DIEGO , July 31, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2019 financial results and provide a corporate update on Wednesday, August 7, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live
View HTML
Toggle Summary Arena Pharmaceuticals Announces First Subject Dosed in CAPTIVATE Phase 2 Trial Evaluating Olorinab in Abdominal Pain Associated with Irritable Bowel Syndrome
- CAPTIVATE clinical trial initiated and enrollment progressing - Evaluating patients with the clinical diagnosis of either constipation or diarrhea predominant irritable bowel syndrome (IBS) - Significant unmet need for pain management in gastrointestinal disorders SAN DIEGO , July 25, 2019
View HTML
Toggle Summary Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
- Significant unmet need for new effective therapies exists in ulcerative colitis - ELEVATE UC clinical trial sites continue to initiate SAN DIEGO , June 17, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in ELEVATE UC 52, the
View HTML
Toggle Summary Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference on June 19
SAN DIEGO , June 13, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 , at 1:30 PM
View HTML
Toggle Summary Arena Pharmaceuticals' Presence at Digestive Disease Week (DDW) Reinforces Commitment to the Gastrointestinal Disease Community
- ELEVATE UC Phase 3 global program site initiations - New data for both etrasimod and olorinab SAN DIEGO , May 17, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has initiated sites for its ELEVATE UC Phase 3 global program to evaluate etrasimod 2 mg in
View HTML
Toggle Summary Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO , May 13, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences: UBS Global Healthcare Conference on Monday, May 20 , at 8:30 AM EDT in New York City RBC Capital
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2019 Financial Results
- Etrasimod ELEVATE UC Phase 3 Program expected to initiate mid-year targeting significant unmet need in ulcerative colitis - Multiple first- or best-in-class therapeutics, strong leadership team and liquidity position of approximately $1.3 billion SAN DIEGO , May 8, 2019 /PRNewswire/ -- Arena
View HTML